{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:13:20Z","timestamp":1793196800369,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T00:00:00Z","timestamp":1513123200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s40265-017-0854-6","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T03:54:14Z","timestamp":1513137254000},"page":"123-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis"],"prefix":"10.1007","volume":"78","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,13]]},"reference":[{"issue":"9","key":"854_CR1","first-page":"504","volume":"9","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504\u201313.","journal-title":"Am Health Drug Benefits."},{"key":"854_CR2","unstructured":"World Health Organization. Global report on psoriasis. 2016. http:\/\/www.who.int . Accessed 8 Dec 2017."},{"issue":"1","key":"854_CR3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","volume":"65","author":"A Menter","year":"2011","unstructured":"Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section\u00a06. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137\u201374.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"854_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/PTT.S51490","volume":"2015","author":"D Balak","year":"2015","unstructured":"Balak D. Fumaric acid esters in the management of psoriasis. Psoriasis Targ Ther. 2015;2015(1):9\u201323.","journal-title":"Psoriasis Targ Ther."},{"key":"854_CR5","volume-title":"Dimethyl fumarate for moderate to severe chronic plaque psoriasis","author":"E Okpara","year":"2017","unstructured":"Okpara E. Dimethyl fumarate for moderate to severe chronic plaque psoriasis. Newcastle: Regional Drug & Therapeutics Centre; 2017."},{"issue":"1","key":"854_CR6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11845-016-1470-2","volume":"186","author":"D Smith","year":"2017","unstructured":"Smith D. Fumaric acid esters for psoriasis: a systematic review. Ir J Med Sci. 2017;186(1):161\u201377.","journal-title":"Ir J Med Sci."},{"key":"854_CR7","unstructured":"European Medicines Agency. Summary of product characteristics: Skilarence 30 mg gastro-resistant tablets, Skilarence 120\u00a0mg gastro-resistant tablets. 2017. http:\/\/www.ema.europa.eu . Accessed 8 Dec 2017."},{"key":"854_CR8","unstructured":"European Medicines Agency. Assessment report: Skilarence. 2017. http:\/\/www.ema.europa.eu . Accessed 8 Dec 2017."},{"issue":"4","key":"854_CR9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.jid.5700686","volume":"127","author":"JC Lehmann","year":"2007","unstructured":"Lehmann JC, Listopad JJ, Rentzsch CU, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol. 2007;127(4):835\u201345.","journal-title":"J Invest Dermatol."},{"issue":"9","key":"854_CR10","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/sj.jid.5700859","volume":"127","author":"B Gesser","year":"2007","unstructured":"Gesser B, Johansen C, Rasmussen MK, et al. Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1\/2): possible role for its anti-psoriatic effect. J Invest Dermatol. 2007;127(9):2129\u201337.","journal-title":"J Invest Dermatol."},{"issue":"3","key":"854_CR11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1046\/j.1365-2133.1998.02400.x","volume":"139","author":"HM Ockenfels","year":"1998","unstructured":"Ockenfels HM, Schultewolter T, Ockenfels G, et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol. 1998;139(3):390\u20135.","journal-title":"Br J Dermatol."},{"issue":"4","key":"854_CR12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bjd.13128","volume":"171","author":"AJ Onderdijk","year":"2014","unstructured":"Onderdijk AJ, Balak DMW, Baerveldt EM, et al. Regulated genes in psoriatic skin during treatment with fumaric acid esters. Br J Dermatol. 2014;171(4):732\u201341.","journal-title":"Br J Dermatol."},{"issue":"5","key":"854_CR13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/11533240-000000000-00000","volume":"11","author":"HJ Bovenschen","year":"2010","unstructured":"Bovenschen HJ, Langewouters AM, van de Kerkhof PC. Dimethylfumarate for psoriasis: pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study. Am J Clin Dermatol. 2010;11(5):343\u201350.","journal-title":"Am J Clin Dermatol."},{"key":"854_CR14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2210-4-22","volume":"4","author":"NHR Litjens","year":"2004","unstructured":"Litjens NHR, van Strijen E, van Gulpen C, et al. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol. 2004;4:22.","journal-title":"BMC Pharmacol."},{"issue":"1","key":"854_CR15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/jid.2008.197","volume":"129","author":"M Rostami-Yazdi","year":"2009","unstructured":"Rostami-Yazdi M, Clement B, Schmidt TJ, et al. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol. 2009;129(1):231\u20134.","journal-title":"J Invest Dermatol."},{"issue":"7","key":"854_CR16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00403-010-1061-4","volume":"302","author":"M Rostami-Yazdi","year":"2010","unstructured":"Rostami-Yazdi M, Clement B, Mrowietz U. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res. 2010;302(7):531\u20138.","journal-title":"Arch Dermatol Res."},{"issue":"2","key":"854_CR17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00403-012-1214-8","volume":"304","author":"A Nast","year":"2012","unstructured":"Nast A, Boehncke WH, Mrowietz U, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2012;304(2):87\u2013113.","journal-title":"Arch Dermatol Res."},{"issue":"3","key":"854_CR18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.14947","volume":"176","author":"U Mrowietz","year":"2017","unstructured":"Mrowietz U, Szepietowski JC, Loewe R, et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm\u00ae- and placebo-controlled trial (BRIDGE). Br J Dermatol. 2017;176(3):615\u201323.","journal-title":"Br J Dermatol."},{"key":"854_CR19","unstructured":"Mrowietz U, Szepietowski J, Loewe R, et al. Clinical efficacy of LAS41008 (dimethyl fumarate) in pre-treated vs naive patients with moderate-to-severe chronic plaque psoriasis: post-hoc analysis of the BRIDGE study [abstract no. P1848 plus poster]. In: European Academy of Dermatology and Venerology. 2017."},{"key":"854_CR20","unstructured":"Mrowietz U, Szepietowski J, Loewe R, et al. LAS41008 (dimethyl fumarate) for psoriasis: analysis of the efficacy of treatment according to severity of disease at baseline [abstract no. P1846 plus poster]. In: European Academy of Dermatology and Venereology. 2017."},{"key":"854_CR21","unstructured":"Van de Kerkhof P, Szepietowski JC, Loewe R, et al. Treatment with LAS41008 (dimethyl fumarate) improves health-related quality of life and has a positive impact on the patient benefit index in adults with moderate-to-severe chronic plaque psoriasis: results of the BRIDGE study [abstract P1998 plus poster]. In: European Academy of Dermatology and Venerology. 2016."},{"issue":"6","key":"854_CR22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0190-9622(94)70121-0","volume":"30","author":"PJ Altmeyer","year":"1994","unstructured":"Altmeyer PJ, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol. 1994;30(6):977\u201381.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"854_CR23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0190-9622(89)70071-2","volume":"20","author":"C Nieboer","year":"1989","unstructured":"Nieboer C, de Hoop D, van Loenen AC, et al. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol. 1989;20(4):601\u20138.","journal-title":"J Am Acad Dermatol."},{"issue":"2 Pt 1","key":"854_CR24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(08)80766-9","volume":"22","author":"WM Nugteren-Huying","year":"1990","unstructured":"Nugteren-Huying WM, van der Schroeff JG, Hermans J, et al. Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 1990;22(2 Pt 1):311\u20132.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"854_CR25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2133.2010.10195.x","volume":"164","author":"S Fallah Arani","year":"2011","unstructured":"Fallah Arani S, Neumann H, Hop WC, et al. Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. Br J Dermatol. 2011;164(4):855\u201361.","journal-title":"Br J Dermatol."},{"issue":"1","key":"854_CR26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000247856","volume":"181","author":"C Nieboer","year":"1990","unstructured":"Nieboer C, de Hoop D, Langendijk PN, et al. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica. 1990;181(1):33\u20137.","journal-title":"Dermatologica."},{"issue":"5","key":"854_CR27","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/bjd.13098","volume":"171","author":"F Walker","year":"2014","unstructured":"Walker F, Adamczyk A, Kellerer C, et al. Fumaderm in daily practice for psoriasis: dosing, efficacy and quality of life. Br J Dermatol. 2014;171(5):1197\u2013205.","journal-title":"Br J Dermatol."},{"issue":"7","key":"854_CR28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1468-3083.2012.04596.x","volume":"27","author":"M Inzinger","year":"2013","unstructured":"Inzinger M, Weger W, Heschl B, et al. Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions. J Eur Acad Dermatol Venereol. 2013;27(7):861\u20136.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"3","key":"854_CR29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2005.06728.x","volume":"153","author":"MJ Harries","year":"2005","unstructured":"Harries MJ, Chalmers RJ, Griffiths CE. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol. 2005;153(3):549\u201351.","journal-title":"Br J Dermatol."},{"issue":"3","key":"854_CR30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2230.2007.02389.x","volume":"32","author":"L Brewer","year":"2007","unstructured":"Brewer L, Rogers S. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol. 2007;32(3):246\u20139.","journal-title":"Clin Exp Dermatol."},{"issue":"7","key":"854_CR31","first-page":"603","volume":"7","author":"K Reich","year":"2009","unstructured":"Reich K, Thaci D, Mrowietz U, et al. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis\u2014a retrospective study (FUTURE). J Dtsch Dermatol Ges. 2009;7(7):603\u201311.","journal-title":"J Dtsch Dermatol Ges."},{"issue":"5","key":"854_CR32","first-page":"429","volume":"11","author":"D Thaci","year":"2013","unstructured":"Thaci D, Weisenseel P, Philipp S, et al. Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions\u2014a retrospective evaluation (FACTS). J Dtsch Dermatol Ges. 2013;11(5):429\u201335.","journal-title":"J Dtsch Dermatol Ges."},{"issue":"1","key":"854_CR33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0926-9959(94)00056-6","volume":"4","author":"HB Thio","year":"1995","unstructured":"Thio HB, van der Schroeff JG, Nugteren-Huying WM, et al. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm\u00ae) in psoriasis. J Eur Acad Dermatol Venereol. 1995;4(1):35\u201340.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"5 Pt 1","key":"854_CR34","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0190-9622(08)80228-9","volume":"27","author":"DN Kolbach","year":"1992","unstructured":"Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2\u00a0years of treatment. J Am Acad Dermatol. 1992;27(5 Pt 1):769\u201371.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"854_CR35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/09546634.2015.1050980","volume":"27","author":"R Lijnen","year":"2016","unstructured":"Lijnen R, Otters E, Balak D, et al. Long-term safety and effectiveness of high-dose dimethylfumarate in the treatment of moderate to severe psoriasis: a prospective single-blinded follow-up study. J Dermatol Treat. 2016;27(1):31\u20136.","journal-title":"J Dermatol Treat."},{"issue":"9","key":"854_CR36","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/jdv.14236","volume":"31","author":"DMW Balak","year":"2017","unstructured":"Balak DMW, Hajdarbegovic E, Bramer WM, et al. Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients. J Eur Acad Dermatol Venereol. 2017;31(9):1475\u201382.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"6","key":"854_CR37","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00415-017-8509-9","volume":"264","author":"RJ Gieselbach","year":"2017","unstructured":"Gieselbach RJ, Muller-Hansma AH, Wijburg MT, et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol. 2017;264(6):1155\u201364.","journal-title":"J Neurol."},{"issue":"10","key":"854_CR38","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","volume":"307","author":"K Reich","year":"2015","unstructured":"Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from the German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307(10):875\u201383.","journal-title":"Arch Dermatol Res."},{"issue":"2","key":"854_CR39","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2133.2003.05433.x","volume":"149","author":"JJ Hoefnagel","year":"2003","unstructured":"Hoefnagel JJ, Thio HB, Willemze R, et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol. 2003;149(2):363\u20139.","journal-title":"Br J Dermatol."},{"issue":"12","key":"854_CR40","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","volume":"29","author":"A Nast","year":"2015","unstructured":"Nast A, Gisondi P, Ormerod AD, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris\u2014update 2015\u2014short version\u2014EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277\u201394.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"3","key":"854_CR41","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","volume":"61","author":"A Menter","year":"2009","unstructured":"Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section\u00a04. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451\u201385.","journal-title":"J Am Acad Dermatol."},{"key":"854_CR42","doi-asserted-by":"crossref","unstructured":"Zweegers J, de Jong EM, Nijsten TE, et al. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dutch Society of Dermatology and Venereology. Dermatol Online J. 2014;20(3).","DOI":"10.5070\/D3203021769"},{"issue":"11","key":"854_CR43","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/ddg.13152","volume":"14","author":"T Arnold","year":"2016","unstructured":"Arnold T, Schaarschmidt ML, Herr R, et al. Drug survival rates and reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges. 2016;14(11):1089\u201399.","journal-title":"J Dtsch Dermatol Ges."},{"issue":"2","key":"854_CR44","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjd.12849","volume":"171","author":"N Ismail","year":"2014","unstructured":"Ismail N, Collins P, Rogers S, et al. Drug survival of fumaric acid esters for psoriasis: a retrospective study. Br J Dermatol. 2014;171(2):397\u2013402.","journal-title":"Br J Dermatol."},{"issue":"4","key":"854_CR45","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bjd.15707","volume":"177","author":"M Sticherling","year":"2017","unstructured":"Sticherling M, Mrowietz U, Augustin M, et al. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol. 2017;177(4):1024\u201332.","journal-title":"Br J Dermatol."},{"issue":"3","key":"854_CR46","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","volume":"159","author":"J Schmitt","year":"2008","unstructured":"Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(3):513\u201326.","journal-title":"Br J Dermatol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0854-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0854-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0854-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T10:13:10Z","timestamp":1660126390000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0854-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,13]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0854-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,13]]}}}